<br>        Inclusion Criteria:<br><br>          -  Have type 2 diabetes mellitus (T2DM), based on the World Health Organization (WHO)<br>             classification, for =1 year.<br><br>          -  Use any type of basal insulin (except degludec), including once-or twice-daily human<br>             insulin neutral protamine Hagedom (NPH), insulin detemir, or insulin glargine.<br><br>          -  Have hemoglobin A1c (HbA1c) levels =9.0% according to local laboratory testing at<br>             screening.<br><br>          -  Have body mass index (BMI) =40.0 kilograms/square meter (kg/m^2).<br><br>          -  Have been treated with stable doses of insulin for at least 30 days before screening<br>             with:<br><br>               -  Basal insulin with daily doses ±30% of mean during the last 4 weeks.<br><br>               -  Doses of a basal insulin must be between 0.3 unit/kg/day and 1 unit/kg/day.<br><br>          -  If on metformin, thiazolidinediones (TZDs), sodium glucose co-transporter 2 (SGLT-2)<br>             inhibitors, or dipeptidyl peptidase (DPP4) inhibitors, must be on stable doses for the<br>             last 30 days.<br><br>        Exclusion Criteria:<br><br>          -  Are using prandial, self-mixed, or premixed insulin. Participants using prandial<br>             insulin may be switched to everyday (qd) glargine if investigator judges that the<br>             participant will still meet fasting glucose requirements for randomization.<br><br>          -  Are using insulin pump therapy.<br><br>          -  Have excessive insulin resistance: Defined as >1.0 unit/kg/day as baseline treatment.<br><br>          -  If being treated with sulfonylureas (SUs) before screening, then must have SUs washed<br>             out between screening and randomization.<br><br>          -  Use any of these concomitant medications: morphine, codeine, antidiuretics,<br>             glucagon-like peptide-1 (GLP-1) receptor agonists (for example, exenatide, exenatide<br>             once weekly, lixisenatide or liraglutide), or pramlintide, used concurrently or within<br>             90 days before screening.<br><br>          -  Have hypoglycemia unawareness, defined as confirmed by laboratory test results or by<br>             historical episodes of hypoglycemia <54 mg/dL (3.0 mmol/L) without symptoms.<br><br>          -  Have fasting hypertriglyceridemia >400 mg/dL (>4.5 mmol/L) at screening, as determined<br>             by the local laboratory.<br><br>          -  Have had any episode of severe hypoglycemia (defined by requiring assistance due to<br>             neurologically disabling hypoglycemia) within 6 months before entry into the study.<br><br>          -  Have had 2 or more emergency room visits or hospitalizations due to poor glucose<br>             control in the past 6 months.<br><br>          -  Have had a previous clinically significant episode of ketoacidosis as determined by<br>             the investigator (ketone bodies at fasting and without acidosis is acceptable) in the<br>             past 6 months.<br><br>          -  Have history of renal transplantation, are currently receiving renal dialysis, or have<br>             estimated Glomerular Filtration Rate (eGFR) <60 milliliters/minute.<br><br>          -  Have obvious clinical signs or symptoms of liver disease (excluding nonalcoholic fatty<br>             liver disease), acute or chronic hepatitis, nonalcoholic steatohepatitis, or elevated<br>             liver enzyme measurements.<br><br>          -  Have active or untreated malignancy, have been in remission from clinically<br>             significant malignancy (other than basal cell or squamous cell skin cancer) for less<br>             than 5 years, or are at increased risk for developing cancer or a recurrence of cancer<br>             in the opinion of the investigator.<br>